Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Hironobu Tsukamoto"'
Autor:
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki
Publikováno v:
Case Reports in Gastroenterology, Vol 13, Iss 1, Pp 37-49 (2019)
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in C
Externí odkaz:
https://doaj.org/article/003724b9516e4742b67eccd609200e7a
Autor:
Hiroyasu Iwasaki, Takashi Mizushima, Yuta Suzuki, Shigeki Fukusada, Kenta Kachi, Takanori Ozeki, Kaiki Anbe, Hironobu Tsukamoto, Fumihiro Okumura, Takashi Joh, Hitoshi Sano
Publikováno v:
Gut and Liver, Vol 11, Iss 1, Pp 47-54 (2017)
Background/AimsSelf-expandable metallic stent (SEMS) placement is effective for dysphagia that results from malignant obstruction of the esophagus or gastric cardia; however, stent-related complications may be life-threatening. Thus, the goal of this
Externí odkaz:
https://doaj.org/article/b67c41d10f1c4c9d915eacfca5807e3b
Autor:
Keiji Ozeki, Satoshi Tanida, Tsutomu Mizoshita, Hironobu Tsukamoto, Masahide Ebi, Yoshinori Mori, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Case Reports in Gastroenterology, Vol 6, Iss 3, Pp 765-771 (2012)
Adalimumab (ADA) is applied to induce remission in patients with Crohn’s disease (CD) naïve to chimeric anti-tumor necrosis factor-α (anti-TNF-α), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granu
Externí odkaz:
https://doaj.org/article/754ab37974af4768a32ee66891586047
Autor:
Tsutomu Mizoshita, Satoshi Tanida, Hironobu Tsukamoto, Keiji Ozeki, Takahito Katano, Hirotaka Nishiwaki, Masahide Ebi, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Publikováno v:
Gastroenterology Research and Practice, Vol 2014 (2014)
Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Metho
Externí odkaz:
https://doaj.org/article/431717d2363149bb9ba11fd4ac89dc4c
Autor:
Keiji Ozeki, Satoshi Tanida, Chie Morimoto, Yoshimasa Inoue, Tsutomu Mizoshita, Hironobu Tsukamoto, Takaya Shimura, Hiromi Kataoka, Takeshi Kamiya, Eiji Nishiwaki, Hiroshi Ishiguro, Shigeki Higashiyama, Takashi Joh
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56770 (2013)
BACKGROUND AIMS: Current treatment target toward advanced colorectal cancers is mainly focused on the epidermal growth factor receptor (EGFR) signaling, but its additive effects with chemotherapy are still limited. A disintegrin and metalloproteinase
Externí odkaz:
https://doaj.org/article/ba2a0cad1d9b4d3587c2fc7c2d83e23a
Autor:
Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Hironobu Tsukamoto, Takeshi Kamiya, Hiromi Kataoka, Daitoku Sakamuro, Takashi Joh
Publikováno v:
International Journal of Surgical Oncology, Vol 2012 (2012)
Cisplatin is the most important and efficacious chemotherapeutic agent for the treatment of advanced gastric cancer. Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognit
Externí odkaz:
https://doaj.org/article/9a3521fdc6704a4dac97196bb4d42685
Autor:
Yusuke Kito, Takashi Mizushima, Kenji Urakabe, Ryo Ishihara, Akihisa Minowa, Yuta Suzuki, Kenichi Haneda, Hironobu Tsukamoto, Fumihiro Okumura
Publikováno v:
Kanzo. 63:522-529
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b05dc1547d6181bbce725d1784d1652
https://doi.org/10.2957/kanzo.63.522
https://doi.org/10.2957/kanzo.63.522
Autor:
Yuta Suzuki, Kazuko Watanabe, Yusuke Kito, Kenji Urakabe, Takashi Mizushima, Hironobu Tsukamoto, Kenichi Haneda, Fumihiro Okumura, Yasuaki Fujita, Ryo Ishihara, Akihisa Minowa
Publikováno v:
Kanzo. 62:712-723
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82007b57d50891ff4796462699a76317
https://doi.org/10.2957/kanzo.62.712
https://doi.org/10.2957/kanzo.62.712
Autor:
Takahito Katano, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yuka Suzuki, Satoshi Tanida, Naomi Sugimura, Hironobu Tsukamoto, Yoshihide Kimura, Hiromi Kataoka, Makoto Sasaki, Takashi Mizushima, Tomonori Yamada, Taketo Suzuki
Publikováno v:
Case Reports in Gastroenterology, Vol 13, Iss 1, Pp 37-49 (2019)
Case Reports in Gastroenterology
Case Reports in Gastroenterology
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e6c42450cb494b227faf0b506aed40
https://www.karger.com/Article/FullText/496453
https://www.karger.com/Article/FullText/496453
Autor:
Ryo, Ishihara, Yasuaki, Fujita, Takashi, Mizushima, Yusuke, Kito, Akihisa, Minowa, Yuta, Suzuki, Kenichi, Haneda, Hironobu, Tsukamoto, Fumihiro, Okumura
Publikováno v:
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 118(3)
A 38-year-old man visited our hospital with a complaint of diarrhea and abdominal pain. Contrast-enhanced computed tomography showed that the ileocecal site was intussuscepted to the transverse colon without ischemia. After we reduced intussusception
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95a6c91d393e0a3f26d95605283c27a2
https://pubmed.ncbi.nlm.nih.gov/33692260
https://pubmed.ncbi.nlm.nih.gov/33692260